New use of 2,7,2'-trihydroxy-4,4',7'-trimethoxy-1,1'-diphenanthrene

The invention discloses a pharmaceutical use of 2,7,2'-trihydroxy-4,4',7'-trimethoxy-1,1'-diphenanthrene (TTB) or acceptable salts thereof, and a use of the 2,7,2'-trihydroxy-4,4',7'-trimethoxy-1,1'-diphenylphenanthrene or the acceptable salts or pharmaceutically effective components thereof in preparation of a drug for treating and/or preventing cerebral ischemia-reperfusion injury. The TTB is used as the drug to resist cerebral ischemia-reperfusion injury for the first time, and the prepared drug is verified to be able to resist cerebral ischemia-reperfusion injury through pharmacological experiments. The material is a naturally sourced monomer compound with clear structure, and has the advantages of no toxicity and good therapeutic effect. 本发明公开了2,7,2′-三羟基-4,4′7′-三甲氧基-1,1′-双菲（TTB）或其可接受的盐的药物用途，所述2,7,2′-三羟基-4,4′7′-三甲氧基-1,1′-双菲或其可接受的盐或其为药物有效成分在制备治疗和/或预防脑缺血再灌注损伤药物中的应用。本发明首次采用TTB作为抗脑缺血再灌注损伤的药物，经过药效实验验证，制备得到的药物能抗脑缺血再灌注损伤。本发明材料为天然来源的结构明确的单体化合物，具有无毒、治疗效果好的优势。